Cargando…
Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa
BACKGROUND: Epidermolysis bullosa (EB) comprises inherited mechanobullous dermatoses with considerable morbidity and mortality. While current treatments are symptomatic, a growing number of innovative therapeutic compounds are evaluated in clinical trials. Clinical research in rare diseases like EB,...
Autores principales: | Prodinger, Christine, Diem, Anja, Ude-Schoder, Katherina, Piñón-Hofbauer, Josefina, Kitzmueller, Sophie, Bauer, Johann W., Laimer, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350741/ https://www.ncbi.nlm.nih.gov/pubmed/32650809 http://dx.doi.org/10.1186/s13023-020-01443-3 |
Ejemplares similares
-
Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa
por: Welponer, Tobias, et al.
Publicado: (2021) -
Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network: Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease
por: Laimer, Martin, et al.
Publicado: (2016) -
Epidermolysis bullosa: Advances in research and treatment
por: Prodinger, Christine, et al.
Publicado: (2019) -
Translational perspectives to treat Epidermolysis bullosa—Where do we stand?
por: Prodinger, Christine, et al.
Publicado: (2020) -
Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial
por: Guttmann-Gruber, Christina, et al.
Publicado: (2021)